Enrique Poradosu, Chief Science & Business Officer at Nuvectis Pharma, Inc. (NVCT), bought 670 shares at $16.04 ($10K) on 2022-05-12, disclosed to the SEC on 2022-05-16.
Open-market purchase of $10k NVCT by Chief Science & Business Officer. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $14.76 | 370 | $5K | 53.2% |
| 2 | $16.04 | 300 | $5K | 46.8% |
| Total | $15.33 avg | 670 | $10K | 100% |
| Filing → |
| NVCT | BUY | 2023-03-28 | $6K | — | Filing → |
| NVCT | BUY | 2022-02-08 | $16K | — | Filing → |